Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Rebound For Amgen With Daiichi Biosimilars Deal

Executive Summary

A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.


Related Content

Daiichi’s Japan Filing The First For Denosumab In RA
'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Takeda Returns Selected Assets Under Bumpy Amgen Alliance
ANALYSIS: Unravelling Japan’s Biosimilar Opportunities


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts